SCYX

시장 영업 전: 1.21 -0.02 -1.63%

Scynexis Inc (SCYX)

개요 뉴스 가격 이력 옵션 체인 Financials SCYX 왜 하락? 토론 예측 주식 분할

Relative Volume:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1233)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

최신 SEC 제출 서류

SCYX's Discussions on Twitter

SCYX을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
SCYX Scynexis Inc	1.23	46.67M	135.87M	72.20M	45.09M	1.42
ZTS Zoetis Inc	165.02	74.45B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.49	42.91B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.24	41.98B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.49	24.35B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	11.96	14.28B	15.05B	-883.30M	1.89B	-0.74

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-01-22	개시	Guggenheim	Buy
2021-01-06	개시	Cantor Fitzgerald	Overweight
2018-07-11	업그레이드	Needham	Hold → Buy
2018-06-27	개시	Maxim Group	Buy
2017-10-24	개시	Guggenheim	Buy
2017-07-10	개시	ROTH Capital	Buy
2017-05-09	다운그레이드	Needham	Buy → Hold
2017-03-03	재확인	RBC Capital Mkts	Outperform
2016-10-20	개시	H.C. Wainwright	Buy
2016-10-07	업그레이드	WBB Securities	Buy → Strong Buy
2016-10-03	재개	Brean Capital	Buy
2016-08-17	개시	Guggenheim	Buy
2016-08-09	재확인	Needham	Buy
2016-08-09	업그레이드	WBB Securities	Speculative Buy → Buy
2016-03-28	개시	Brean Capital	Buy
2015-12-29	개시	WBB Securities	Speculative Buy
2015-11-16	재확인	RBC Capital Mkts	Outperform
2015-06-10	개시	Needham	Buy
2014-05-29	개시	Canaccord Genuity	Buy
2014-05-29	개시	RBC Capital Mkts	Outperform

Scynexis Inc 주식(SCYX)의 최신 뉴스

Scynexis Inc (SCYX) 재무 분석

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

SCYX을(를) 다른 주식과 비교

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc 주식(SCYX)의 최신 뉴스

FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com

Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail

SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.

SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com

SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times

SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan

SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World

SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St

Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com

Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com

SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa

SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com

SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada

Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle

SCYNEXIS announces new $50 million equity sales agreement - Investing.com India

SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan

SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance

SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance

SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times

SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat

CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha

Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily

Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada

Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks

Xero buys South African firm for $115m in 'departure' - New Zealand Herald

SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat

Scynexis CEO acquires $27,400 in company stock - Investing.com

Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA

Better than expected profits forecast for security tech company - The Business Desk

Synopsys Inc. stock rises Friday, still underperforms market - MarketWatch

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average of $1.83 - MarketBeat

SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook - TipRanks

Scynexis Inc (SCYX) 재무 분석

매출

순이익

현금흐름

주당 순 이익

SCYX과 유사한 종목